Kevin Kunzmann

Ian Pitha, MD, PhD, argues that leveraging large-scale utilization data to identify the highest-impact medications could help the field get ahead of supply disruptions before they reach patients.

Pitha discusses how ophthalmic drug shortages — more frequent and longer-lasting than the national average — are threatening adherence to glaucoma therapy.

Paula Anne Newman-Casey, MD, MS, explains the multifactorial needs and her decades-long research that resulted in the SEE program for glaucoma patients.

The 6-month Support, Educate, Empower (SEE) program was associated with a 20% improvement in glaucoma treatment adherence and reduced distress among adult patients.

University of Utah data show US ophthalmic drug and eye drop shortages last longer and occur more often, affecting local and systemic medications equally.